BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
      • Artificial intelligence
    • Coronavirus
    • Israel
    • IVDs on the rise
    • Radiopharmaceuticals
    • Rise of obesity
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, December 11, 2023
Home » Topics » Newco news

Newco news
Newco news RSS Feed RSS

Photo of Nomic's three co-founders

Nomic in $17M series A funding for high-throughput proteomic platform

Dec. 8, 2021
By Meg Bryant
No Comments
Protein profiling startup Nomic Bio has secured $17 million in an oversubscribed series A financing led by Lux Capital. The funds will be used to expand the company’s servicing and manufacturing labs in Montreal and Boston, to broaden access to its proteomic platform by scaling profiling capacity to 100,000 samples per quarter starting in the second quarter of 2022 and by scaling its protein-detection method, called nELISA, to 500 on-boarded proteins.
Read More
Man wearing Ophthalmic Sciences' VR headset

Ophthalmic Sciences eyes 2023 for launch of AI device for glaucoma

Dec. 6, 2021
By Catherine Longworth
No Comments
Israeli startup Ophthalmic Sciences Ltd. is targeting 2023 for regulatory clearance of its artificial intelligence (AI)-based contactless intraocular pressure (IOP) measuring device, IO Perfect. The technology, which combines AI visual analysis in a virtual reality headset, enables remote monitoring of glaucoma. The device is designed to be used at home, in eye clinics, emergency room departments, pharmacies and primary physician settings.
Read More
DNA
Newco news

Loqus23 targeting DNA damage repair processes for Huntington’s, other TRDs

Nov. 23, 2021
By Nuala Moran
No Comments
LONDON – Newco Loqus23 Therapeutics Ltd. has closed a £7 million (US$9.4 million) extension of its seed round, providing the means to progress its lead small-molecule program in Huntington’s disease through lead optimization. The extended round, from the Novartis Venture Fund and the U.K. government-backed Dementia Discovery Fund, follows an initial seed investment of £4.5 million by DDF in 2019, that was not made public at the time.
Read More
Suzanne Saffie-Siebert, founder and CEO, Sisaf
Newco news

Sisaf to move siRNA program for bone growth disorder into the clinic in 2022

Nov. 11, 2021
By Cormac Sheridan
No Comments
DUBLIN – Sisaf Ltd. has exercised an option on an Italian preclinical program to treat a rare bone disorder, autosomal dominant osteopetrosis type 2, with an siRNA molecule, which it will deliver with its in-house Bio-courier technology.
Read More
Hand holding money plant
Newco news

Recently launched Oxitope aims to exploit link between oxidative stress and disease

Oct. 28, 2021
By Nuala Moran
No Comments
LONDON – Four decades of academic research at the University of California, San Francisco, is to be translated through to the clinic with funding from a €1 million (US$1.2 million) European Commission grant. The money, awarded to a Dutch/German consortium will fund the generation and optimization of antibodies designed to neutralize oxidized phospholipids that mediate inflammatory changes in a swathe of diseases. The consortium that won the Eurostars award is led by Oxitope Pharma BV.
Read More
Pill over molecule structures
Newco news

Sapreme hatches endosomal escape plans with $17M series A round

Oct. 7, 2021
By Cormac Sheridan
No Comments
DUBLIN – Sapreme Technologies BV is taking a novel approach to the extraordinary inefficiency of intracellular delivery of macromolecular drugs by developing a series of compounds that can dramatically improve the rate with which drugs such as proteins and oligonucleotides can escape the endosome.
Read More
Petri dish and capsules
Newco news

Micreos sidesteps antibiotic resistance, targeting superbugs with $37M for endolysin

Oct. 4, 2021
By Richard Staines
No Comments
Developing the next generation of antibiotics is proving to be a major problem, with research reaching an almost standstill due to a lack of funding because of the poor return on R&D investment from the products.
Read More
Smart Drain device image

Ordinary drywall screw could be key to treating collapsed lung

Oct. 1, 2021
By David Godkin
No Comments
TORONTO – Smart Biomedical Inc. has developed a tool it said will vastly improve the chances of recovery for patients suffering from a collapsed lung.
Read More
Startup key, rocket icon
Newco news

Startup Accession aiming to create new generation of immunotherapy

Sep. 27, 2021
By Nuala Moran
No Comments
LONDON – The scientific pioneer behind T-cell receptors has taken the helm of a new biotech he believes has the technology to overcome current shortcomings of cancer immunotherapy. Bent Jakobsen, co-founder and long-term chief scientific officer of Immunocore plc and of CAR T-cell specialist Adaptimmune plc, is now CEO of Accession Therapeutics Ltd., set up to develop what is claimed as the first oncolytic virus to be genetically engineered to exclusively infect cancer cells.
Read More
Hand holding lightbulb

Startup Somne collars new solution for treating obstructive sleep apnea

Sep. 16, 2021
By David Godkin
No Comments
Newly launched startup Somne Inc. plans to give CPAP machines a run for their money by replacing CPAP masks and hoses for treating obstructive sleep apnea with a gentler collar encircling the patient’s neck. The new device uses variable negative pressure to ensure users get a good night’s sleep instead of positive airway pressure employed by companies such as Resmed Inc. and Philips Respironics Inc.
Read More
Previous 1 2 … 20 21 22 23 24 25 26 27 28 … 46 47 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 11, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for December 11, 2023.
  • Coronavirus, mRNA and syringe

    Off-target immune response from modified mRNA impacts future development

    BioWorld
    The Nobel Prize-winning modification that prevents the innate immune system from recognizing injected mRNA as foreign and blocking transcription of the protein it...
  • Stock chart with falling red arrow

    ‘Ridiculous’ site-based hitches mar Biovie phase III in Alzheimer’s

    BioWorld
    For the second time this week, a contract research organization has come under fire for trial-conduct issues – criticism leveled most recently by Biovie Inc.,...
  • Feet and scale

    Waging the losing battle: Altimmune takes on challengers as Pfizer falls back

    BioWorld
    Altimmune Inc.’s peptide-based glucagon-like peptide-1/glucagon dual receptor agonist pemvidutide hiccupped in a phase I study earlier this year but has bounced...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing